升高的XI因子与第一个和复发的未知来源的左前庭尾血栓有关
Aleksandra Banaś1, Szymon Glanowski1, Michał Ząbczyk2,3
1Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
Thrombosis and haemostasis
|September 29, 2025
概括
升高的XI因子 (FXI) 与左心房附属体血栓 (LAAT) 的形成和复发有关. 较高的FXI水平预测LAAT复发和脑血管事件,这表明在识别需要延长抗凝剂的患者方面发挥了作用.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 血栓形成和血液静止.
背景情况:
- 未知来源的左心房附属体血栓 (LAAT) 涉及密集的,不易溶解的纤维素网络.
- 升高的XI因子 (FXI) 涉及到血栓栓塞事件,包括左心室血栓.
研究的目的:
- 调查LAAT患者的FXI水平是否增加.
- 为了确定高的FXI是否会导致LAAT复发和相关并发症.
主要方法:
- 一项病例对照研究将36名LAAT患者与36名匹配的对照人进行了比较,所有人都服用抗凝药.
- 评估了血FXI,·维勒布兰德因子 (vWF),凝块透性 (Ks),凝块溶解时间 (CLT),纤维化解,血栓生成和血小板标志物.
- 在中位数10年随访期间评估缺血性脑血管事件和LAAT复发.
主要成果:
- LAAT患者的FXI水平比对照患者高14% (p < 0.001);FXI>120%更频繁 (p = 0.0015).
- 更高的FXI与纤维素原和延长的CLT相关,与vWF和KS相反.
- 基线FXI>120%的患者经历了大多数LAAT复发 (10/11) 和脑血管事件 (18/23) (两者p < 0.001).
- FXI升高与LAAT复发 (OR 2.73) 和脑血管事件 (OR 1.79) 有关.
结论:
- 较高的FXI水平与来源不明的LAAT,其复发以及抗凝药撤销后的大脑血管事件有关.
- FXI可以作为生物标志物来识别可能从长期抗凝治疗中受益的LAAT患者.
- 需要进一步的研究来验证FXI在指导LAAT抗凝策略中的作用.
相关概念视频
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
Venous Thrombosis I: Introduction
373
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
373
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Extrinsic and Intrinsic Pathways of Hemostasis
12.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K


